Screen failure rates average 57% in CNS studies, compared with 36.3% across other therapeutic areas, and Avance Clinical points to more than 50 CNS trials completed over the past five years as it launches a dedicated CNS Center of Excellence aimed at compressing those inefficiencies.
The CRO’s new unit formalizes an end-to-end offering for neurological drug development from first-in-human through Phase III, anchored in Australia’s rapid-start regulatory framework and 43.5% R&D tax incentive, with structured pathways to expand into multi-regional late-phase programs. The center consolidates CNS-specific protocol design, multi-jurisdiction regulatory strategy, specialized site networks, targeted recruitment, and data operations for complex endpoints. Avance has tapped neurologist and industry veteran Francesco Bibbiani to lead the effort, layering therapeutic depth onto a platform that includes in-house regulatory teams, access to more than 2,000 specialized sites globally, and a defined Australia-to-global transition process.
Strategically, this is a bid to capture a disproportionate share of CNS programs from smaller biotechs that need early de-risking and capital efficiency before committing to expansive registrational footprints. CNS pipelines are surging, but execution has lagged due to stringent inclusion criteria, rater variability, placebo response, and imaging- or device-heavy assessments that strain sites. By productizing an “accelerate in Australia, scale globally” model under a single governance structure, Avance is positioning against larger full-service CROs whose CNS units can be slower to mobilize for sub-scale sponsors. The center also reads as a response to tightening venture markets; sponsors are seeking earlier go/no-go signals and tighter operational control around screen failures, protocol deviations, and endpoint integrity.
For sponsors, the immediate appeal is cycle-time reduction and budget predictability in early development with a prebuilt bridge to U.S. and EU geographies. If the center can materially cut screen failure rates and stabilize endpoint quality, it could lower the sample sizes and site counts required to achieve power, with clear downstream cost implications. For sites, the model may concentrate CNS work within experienced networks and raters, which can improve data quality but risks diverting volume away from generalist centers. Regulators could see more Australian-origin data anchoring pivotal strategies; that places a premium on early scientific advice and alignment on digital measures, central rating, and imaging read paradigms to avoid bridging surprises. Vendors across rater training, eCOA, wearables, and imaging analytics stand to benefit if Avance standardizes tech stacks across programs rather than running bespoke pilots.
What matters next is execution beyond Australia. The center will be judged on its ability to port early-phase operational assumptions into North America, Europe, and Asia without inflating timelines or compromising data continuity. Key questions include whether digital and functional endpoints validated in Australian cohorts translate cleanly across languages and care settings, how the model addresses diversity expectations in later phases, and whether rater standardization holds at scale. Watch for metrics on startup speed, realized screen-failure reductions, rater drift, and regulatory acceptance of early Australian data packages in parallel with FDA/EMA interactions. Competitive response from larger CROs—through tighter CNS pods, tech partnerships, or targeted acquisitions—will indicate whether Avance’s specialization is setting the pace or simply narrowing a gap.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
